Udg Healthcare (UDG) Receives Buy Rating from Peel Hunt
Several other research firms also recently issued reports on UDG. Numis Securities restated a reduce rating on shares of Udg Healthcare in a research report on Wednesday, August 8th. Berenberg Bank increased their target price on Udg Healthcare from GBX 815 ($10.51) to GBX 850 ($10.96) and gave the stock a hold rating in a research report on Wednesday, June 6th. Liberum Capital restated a buy rating and set a GBX 884 ($11.40) target price on shares of Udg Healthcare in a research report on Wednesday, August 8th. Barclays started coverage on Udg Healthcare in a research report on Thursday, May 17th. They set an equal weight rating and a GBX 875 ($11.29) target price on the stock. Finally, Jefferies Financial Group upgraded Udg Healthcare to a buy rating and dropped their target price for the stock from GBX 895 ($11.55) to GBX 890 ($11.48) in a research report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Hold and an average target price of GBX 850.67 ($10.97).
LON:UDG opened at GBX 710 ($9.16) on Tuesday. Udg Healthcare has a 1 year low of GBX 690 ($8.90) and a 1 year high of GBX 963 ($12.42).
Udg Healthcare Company Profile
UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services to the healthcare industry in the Republic of Ireland, the United Kingdom, North America, and internationally. The company operates through three segments: Ashfield, Sharp, and Aquilant.
Further Reading: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Udg Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Udg Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.